ライフサイエンスコーパス: ASA

1 ASA at 1,000 muM enhances osteogenic potential of PDLSCs

2 ASA had equal effects on left ventricular outflow tract

3 ASA modulates the expression of growth factor-associated

4 (ASA Plavix Feasibility Study With Watchman Left Atrial A

5 ASA treatment increased levels of ASA-triggered lipoxin

6 ASA upregulated the expression of genes that could activ

7 ASA users without current or past H pylori infections wh

8 ASA was the only As species detected in chicken feed sam

9 ASA-anticoagulant and TRIP were associated with the high

10 AAE (30.2%; 95% CI: 25.6%-34.3%; p<0.0001), ASA (37.9%; 95% CI: 29.2%-45.6%; p<0.0001), ARERs (25.6%

11 ran exposure (p < 0.0001), age (p < 0.0001), ASA use (p < 0.0003), and diabetes (p = 0.018) as signif

12 Patients were categorized into 3 groups: (1) ASA 81 mg+dipyridamole 75 mg daily (n = 26) with a targe

13 , whereas 66.9% of institutions performed 10 ASA procedures or fewer during the study period.

14 of 2 to 3 from June 2006 to August 2009; (2) ASA 81 mg daily (n = 18) from September 2009 to August 2

15 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was partially due to

16 2011 with a target INR of 1.5 to 2; and (3) ASA 325 mg daily from September 2011 to November 2014 wi

17 ion was 39 (anticoagulant-antiplatelet), 34 (ASA-anticoagulant), 67 (ASA-antiplatelet), and 45 (TRIP)

18 on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor ne

19 bond releasing the 5-ASA or a pH-dependent 5-ASA packaging system that permitted release in the dista

20 6 months prior to and 12 months following 5-ASA initiation (index date).

21 c non-pharmacy claims, at least 30 days of 5-ASA treatment and at least one corticosteroid prescripti

22 number of alternative forms of delivery of 5-ASA were developed consisting of either a similar sulfas

23 In general, women on 5-ASA, thiopurine, or anti-tumor necrosis factor (TNF) mon

24 moderate disease flare while on optimized 5-ASA or thiopurine therapy should be managed with systemi

25 5 for a UC diagnosis and at least one oral 5-ASA prescription on or after the first observed UC diagn

26 herent with their prescribed doses of oral 5-ASA.

27 Oral and rectal 5-ASA are recommended first-line therapy for mild to moder

28 As a result, 5-ASA-containing medications continue to provide a valuabl

29 tibacterial agent, and 5-amino-salicylate (5-ASA), an anti-inflammatory agent.

30 target a therapeutic concentration of the 5-ASA component of the medication primarily in the colon,

31 l destruction of an azo-bond releasing the 5-ASA or a pH-dependent 5-ASA packaging system that permit

32 nclusion criteria: 72% were nonadherent to 5-ASA treatment (n=1,217) and 28% were adherent (n=476) in

33 corticosteroid therapy, with transition to 5-ASA, thiopurine, anti-TNF (with or without thiopurine or

34 t-antiplatelet), 34 (ASA-anticoagulant), 67 (ASA-antiplatelet), and 45 (TRIP) patients.

35 reported preoperative comorbidities (41.8%), ASA status (11.3%), and HIV status (7.8%), with a smalle

36 s that enhance the residual arylsulfatase A (ASA) activity found in patients with metachromatic leuko

37 (NPs) that are deficient in arylsulfatase A (ASA) activity.

38 ery of the lysosomal enzyme arylsulfatase A (ASA).

39 the introduction of alcohol septal ablation (ASA) for the treatment of obstructive hypertrophic cardi

40 l myectomy (SM) and alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy have bee

41 and survival after alcohol septal ablation (ASA) in patient with hypertrophic cardiomyopathy.

42 malic (MA), oxalic (OA), or acetylsalicylic (ASA) acid at three concentrations (1, 2 and 3mM) on the

43 Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with cor

44 cation test (DPT) with acetylsalicylic acid (ASA) during 2005-2012 (V1) were included (n=38).

45 new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events i

46 apy, 25,458 (35%) with acetylsalicylic acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA

47 is study, we show that acetylsalicylic acid (ASA) treatment is able to significantly improve SHED-med

48 salicylic acid (SA) or acetylsalicylic acid (ASA) treatments during on-tree cherry growth and ripenin

49 care products (PPCPs) [acetylsalicylic acid (ASA), 2,5-dihydroxybenzoic acid (DBA), 2-phenylphenol (P

50 he organoarsenic additives p-arsanilic acid (ASA), roxarsone (ROX) and nitarsone (NIT) in livestock f

51 Argininosuccinic aciduria (ASA) is an autosomal recessive urea cycle disorder cause

52 deficiency causes argininosuccinic aciduria (ASA), the second most common urea-cycle disorder, and le

53 tic enlargement: the "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis an

54 ilure (6.2%, 7.6%, and 2.4%; P < .001) after ASA in higher-volume centers.

55 class (P=0.106), or syncope (P=0.426) after ASA.

56 remained a marker of reduced survival after ASA with a 5-fold increased risk of all-cause mortality

57 l outcome was assessed 0.6+/-0.6 years after ASA.

58 al status was obtained 7.9+/-4.0 years after ASA.

59 yses, testing was associated with older age, ASA (American Society of Anesthesiologists) class >1, hy

60 All ASA fusion proteins were enzymatically active and target

61 idespread use of amorphous aluminosilicates (ASA) in various industrial catalysts, the nature of the

62 ve shown that ginger constituents ameliorate ASA-induced gastric ulceration.

63 cts clinical criteria for eligibility for an ASA challenge and/or desensitization.

64 In an ASA subject with severe hypertension refractory to antih

65 hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable.

66 r indicates that for U.S. PLATO patients, an ASA dose >300 mg was not a significant interaction for v

67 tistics facilitates auditory-scene-analysis (ASA).

68 squares (PLS) and assigned signal analysis (ASA).

69 On multivariate analysis, ASA class and the LOS remained most strongly associated

70 ue mutants than predicted HSEbeta (0.37) and ASA (0.43).

71 difference in sex, age, body weight, BMI and ASA distribution between two groups.

72 Patient demographics and ASA use were assessed descriptively and as covariates.

73 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was partially due to the low-density

74 l was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

75 djustment for age, sex, body mass index, and ASA-performing center.

76 are independently associated with POMR, and ASA and case mix were not included, risk adjustment migh

77 etermination of PPCPs in a sewage sample and ASA and FP in drug preparations.

78 eptal reduction therapy performed few SM and ASA procedures, which is below the threshold recommended

79 sed on tertiles of hospital volume of SM and ASA.

80 us, (2) quality of care measures: statin and ASA use, (3) healthcare resource utilization: emergency

81 In patients >/=75 years and ASA I-II, laparoscopic resection was associated with 46%

82 ified for age (<75 years or >/=75 years) and ASA status (I-II/III-IV).

83 , mean American Society of Anesthesiologist (ASA) score 3.1, and mean body mass index (BMI) 34.1 +/-

84 edian American Society of Anesthesiologists (ASA) class was 2 (general surgery: 2; upper GI: 3; small

85 , and American Society of Anesthesiologists (ASA) classification (I/II/III; TVAE: 57.1%/41.8%/1.0% vs

86 ndex, American Society of Anesthesiologists (ASA) score, difficult anatomy, and need for extensive ad

87 , and American Society of Anesthesiologists (ASA) score.

88 bic sizing agent, alkenylsuccinic anhydride (ASA).

89 nt-antiplatelet, aspirin (ASA)-antiplatelet, ASA-anticoagulant, or triple therapy (ie, TRIP, anticoag

90 herapy (ie, TRIP, anticoagulant-antiplatelet-ASA) were identified from the national pharmacy database

91 ell culture model was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

92 diastole is that the atrial short-axis area (ASA) is smaller than the ventricular short-axis area (VS

93 growth spurt of added apposed surface area (ASA)>200 mum2/d centered on a single age at postnatal da

94 s including solvent accessible surface area (ASA), residue depth (RD) and contact numbers (CN).

95 ortional to solvent-accessible surface area (ASA), whereas the HY values of alkanes depend on special

96 tations following ASA because, in this area, ASA still seems inferior to myectomy.

97 id-insoluble ash (AIA) and acid-soluble ash (ASA) fractions using HCl.

98 Aspirin (ASA) treatment significantly reduced lung platelet seque

99 Taking an aspirin (ASA) regularly after being diagnosed with colon cancer i

100 trations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emb

101 scribed anticoagulant-antiplatelet, aspirin (ASA)-antiplatelet, ASA-anticoagulant, or triple therapy

102 pholipids, which can be enhanced by aspirin (ASA) treatment.

103 The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) r

104 of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients

105 of research suggests daily low-dose aspirin (ASA) reduces heart diseases and colorectal cancers.

106 reatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI,

107 i infection among users of low-dose aspirin (ASA) who are at high risk for developing ulcers.

108 to antiplatelet therapy, including aspirin (ASA) dosing, is uncertain.

109 rning to avoid maintenance doses of aspirin (ASA) >100 mg/daily.

110 s study investigates the effects of aspirin (ASA) on the proliferative capacity, osteogenic potential

111 There are limited data on aspirin (ASA) desensitization for patients with coronary artery d

112 ut HIV provider practices regarding aspirin (ASA) for primary prevention of CVD.

113 mans with HD using an amyloid seeding assay (ASA), which is based on the propensity of misfolded prot

114 he pathogenesis of aspirin-sensitive asthma (ASA).

115 cerbation (AAE) or acute status asthmaticus (ASA).

116 he SC 59 and (SSN76)FC6608 RED KAFIR BAZINE (ASA N23) cultivars, which have an average RS content of

117 Severe septal hypertrophy before ASA remained a marker of reduced survival after ASA with

118 rated that the anatomical difference between ASA and VSA provides the basis for generating a hydrauli

119 Fusion proteins between ASA and the protein transduction domain of the human imm

120 ndings suggest that the relationship between ASA and VSA, and the associated hydraulic force, should

121 KA therapy was significantly higher for both ASA (IRR: 2.00; 95% CI: 1.88 to 2.12) and dual-therapy (

122 functions and canonic pathways activated by ASA treatment.

123 1 and the percentage of reactions induced by ASA/ibuprofen were significantly lower in Group A (P=.00

124 They received enteric-coated ASA after ulcer healing.

125 operative variables (eg, age, comorbidities, ASA, wound classification), procedure type (eg, laparosc

126 stematically reviewing all studies comparing ASA with myectomy with long-term follow-up, (aborted) su

127 We assessed concomitant ASA use and its association with clinical outcomes among

128 mine if and when the benefits of concomitant ASA outweigh the risks in AF patients already on OAC.

129 o assess factors associated with concomitant ASA therapy.

130 iving OAC are often treated with concomitant ASA, even when they do not have cardiovascular disease.

131 Improvement may be achieved by: 1) confining ASA to hypertrophic cardiomyopathy centers of excellence

132 ensitization, 253 patients (80.3%) continued ASA for at least 12 months.

133 ild-type mice and arylsulfatase A-deficient (ASA knockout) mice that accumulate sulfatides.

134 ara-nitrocatechol sulfate (pNCS), detectable ASA residual activity were observed in primary and SV40t

135 y, the strongest interaction is the diabetes-ASA interaction.

136 High-dose ASA in Heart Mate II patients treated concomitantly with

137 New users of low-dose ASA for secondary prevention of cardiovascular events, a

138 cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within the prior 3 years.

139 Low-dose ASA use within 24 hours of CABG is independently associa

140 m treatment with ticagrelor 60 mg + low-dose ASA yields a cost-effectiveness ratio suggesting interme

141 one, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA.

142 , or ticagrelor 90 mg twice daily + low-dose ASA.

143 f uncomplicated PUD in new users of low-dose ASA.

144 empirically and includes three risk factors: ASA (American Society of Anesthesiologists) physical sta

145 A robust fluorescence ASA assay was developed in high-density 1,536-well plate

146 ntions and pacemaker implantations following ASA because, in this area, ASA still seems inferior to m

147 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was parti

148 4) use of appropriate amounts of alcohol for ASA.

149 The quantitative cell-based HTS assay for ASA generated strong statistical parameters when tested

150 in a BBB cell culture model was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

151 that GAS can be a therapeutic equivalent for ASA in inflammatory and proliferative diseases without t

152 ated risk of MI was significantly higher for ASA (incidence rate ratio [IRR]: 1.54; 95% confidence in

153 in delivery was, however, increased only for ASA-ApoE-II.

154 The relative standard deviations (RSDs) for ASA, ROX and NIT determined from five measurements of th

155 ficant increase in lipid rafts isolated from ASA knockout mice.

156 Risk factors of age, gender, ASA (American Society of Anesthesiologists) grade, and s

157 low preoperative albumin levels, and higher ASA (American Society of Anesthesiologists) status of th

158 difficult anatomy, liver biopsy, and higher ASA score increased operative duration.

159 Patients with delirium had higher ASA and Charlson comorbidity index scores.

160 Among patients with successful in-hospital ASA desensitization, 253 patients (80.3%) continued ASA

161 ciated with detergent-resistant membranes in ASA-deficient cells and showed a significant decrease in

162 ion, and normalized the production of OLs in ASA-deficient NPs.

163 ntribute to the highly variable phenotype in ASA patients if expressed at high levels.

164 Predictors of wound complications included ASA score, diabetes, smoking, number of previous abdomin

165 trongly associated with readmission included ASA class, albumin less than 3.5, diabetes, inpatient co

166 n incubation with lysine acetylsalicylate (L-ASA; 1-300 mumol/L) on 1) platelet function under shear

167 smolar mannitol, 1) reduced the ability of L-ASA to inhibit platelet responses to agonists; 2) did no

168 hromboxane synthesis; and 3) prevented the L-ASA-induced activation of the NO/cGMP/PKG pathway.

169 sponses to agonists; 2) did not modify the L-ASA-induced inhibition of thromboxane synthesis; and 3)

170 heart rate, hemoglobin level, albumin level, ASA (American Society of Anesthesiologists) score, surgi

171 DFT band structure calculations (TB-LMTO-ASA) were performed with ordered model structures which

172 Lys-ASA-induced cysLT generation and MC activation depended

173 Lysine aspirin (Lys-ASA)-challenged PGE2 synthase-1 null mice exhibit sustai

174 eceptor agonist blocked the responses to Lys-ASA by approximately 90%; EP3 and EP4 agonists were also

175 eral blood samples and activated with lysine ASA (LysASA).

176 black box warning for the use of maintenance ASA doses >100 mg with ticagrelor is inappropriate for p

177 Mechanistically, ASA treatment upregulates the telomerase reverse transcr

178 artile range [IQR]: 51-75) years; the median ASA score was 2 (IQR: 2-2).

179 pectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor)

180 Therefore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulc

181 5% CI, 0.41-1.35; P = 0.33) compared with no ASA.

182 ients (n=2543) on OAC also received ASA (OAC+ASA).

183 Use of OAC+ASA was associated with significantly increased risk for

184 7) were significantly higher in those on OAC+ASA compared with those on OAC alone.

185 an one third of patients (39%) receiving OAC+ASA did not have a history of atherosclerotic disease, y

186 Patients receiving OAC+ASA were more likely to be male (66% versus 53%; P<0.000

187 ent procedure for extraction and analysis of ASA, DBA, PP, and FP in these samples.

188 A scoring system on the basis of ASA class and the LOS may help stratify readmission risk

189 in reducing lysosomal storage in the CNS of ASA-knock-out mice treated by ERT.

190 prospective study, we recruited 3 cohorts of ASA users (</=160 mg/day).

191 Combination of ASA and VKA therapy was not associated with a lower risk

192 Discontinuation of ASA in the 62 patients (19.7%) who had responded to the

193 cking regarding optimal timing and dosing of ASA.

194 centers including patients with a history of ASA sensitivity undergoing coronary angiography with int

195 A total of 330 patients with history of ASA sensitivity with known/suspected stable coronary art

196 ASA treatment increased levels of ASA-triggered lipoxin (ATL; 15-epi-lipoxin A4), and bloc

197 Escalating likelihood of ASA prescription with increasing CVD-related comorbidity

198 icantly reduced for patients taking 81 mg of ASA (1.4%) compared with 325 mg (2.9%) or none (3.9%).

199 ivariate analysis demonstrated that 81 mg of ASA decreased mortality risk by 66% (OR, 0.34; 95% CI, 0

200 CI, 0.18-0.66; P < 0.01), whereas 325 mg of ASA had no mortality benefit (OR, 0.74; 95% CI, 0.41-1.3

201 er-directed gene therapy in a mouse model of ASA.

202 Odds of ASA prescription more than doubled for each additional C

203 ) receptor has a role in the pathogenesis of ASA.

204 .70), whereas being in the lowest tertile of ASA by volume was not independently associated with an i

205 pylori-negative (past and present) users of ASA who developed bleeding ulcers (n = 118).

206 he average-risk cohort included new users of ASA without a history of ulcers (n = 537).

207 the clinical and biochemical variability of ASA.

208 Collection and analysis of data on ASA challenges and desensitizations from 10 allergy cent

209 an INR at event, 2.0), and in 38 patients on ASA 325 mg (54%; 1.4 events per patient year; mean INR a

210 Patients on ASA 325 mg had a higher adjusted hazard ratio of 2.9 (95

211 year; mean INR at event, 2.2), 4 patients on ASA 81 mg (22%; 0.38 events per patient year; mean INR a

212 Hemorrhagic events occurred in 6 patients on ASA 81 mg+dipyridamole (26%; 0.42 events per patient yea

213 fibers after treatment with either lignin or ASA.

214 Thus, preharvest treatments with SA or ASA could be promising tools to improve sweet cherry qua

215 Heart' and 'Sweet Late', were used and SA or ASA treatments, at 0.5, 1.0 and 2.0mM concentrations, we

216 all patients who were hospitalized for SM or ASA in a nationwide inpatient database from January 1, 2

217 to better describe the solvent exposure over ASA, CN and RD in many applications.

218 ent sources to facilitate active and passive ASA.

219 ry and SV40t fibroblasts from a MLD patient (ASA-I179S) cultured in multi-well plates.

220 complex contexts (OR 0.59), sicker patients (ASA grade (II, III/V: OR 0.81, 0.77)), teaching cases (O

221 ch Council GLOBVAC Program and Bionor Pharma ASA.

222 Preoperative ASA administration is associated with reduced morbidity

223 cording to the time of the last preoperative ASA dose: (1) 24 hours or less preoperatively (n = 1173)

224 tandard deviation 7.7]), 64% were prescribed ASA-antiplatelet and anticoagulant-antiplatelet and 6% w

225 can American), only 66 (17%) were prescribed ASA.

226 rs or older, Asian or African American race, ASA (American Society of Anesthesiologists) class 3 or m

227 All patients underwent a rapid ASA (5.5 hours) desensitization procedure.

228 Among 397 patients who qualified to receive ASA (mean age, 52.2 years, 94% male, 36% African America

229 nt therapy were randomly assigned to receive ASA 100 mg/d (n = 176) or LMWH enoxaparin 40 mg/d (n = 1

230 of AF patients (n=2543) on OAC also received ASA (OAC+ASA).

231 fewer than 1 in 5 patients in need received ASA for primary CVD prevention.

232 g 2010 to determine the proportion receiving ASA for primary prevention of CVD and identify factors a

233 s was not standardised, and only NZ recorded ASA status and complete post-discharge mortality.

234 e sex, but not ethnicity, geographic region, ASA use, or clopidogrel use.

235 r after absorption to simultaneously release ASA and [6]-gingerol.

236 They resumed ASA after ulcer healing and H pylori eradication.

237 cute lung injury (TRALI), Boc2 also reversed ASA protection, and treatment with ATL in both LPS and T

238 ri infection can be used to assign high-risk ASA users to groups that require different gastroprotect

239 lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative

240 of pyruvate and beta-aspartate semialdehyde (ASA) to form a cyclic product which dehydrates to form d

241 We assessed the utility of testing ASA users with a high risk of ulcer bleeding for H pylor

242 In volunteers, VSA was greater than ASA during 75-100% of diastole.

243 lower risk of first-time MI and stroke than ASA monotherapy.

244 l of congenital human NO deficiency and that ASA subjects could potentially benefit from NO supplemen

245 restriction is based on the hypothesis that ASA doses >100 mg somehow decreased ticagrelor's benefit

246 These data indicate that ASA treatment is a practical approach to improving SHED-

247 rt of the reason for this difference is that ASA is limited by the route of the septal perforators, w

248 Our data show that ASA, in addition to being a classical urea-cycle disorde

249 Multivariate analysis showed that ASA within 24 hours preoperatively was associated with r

250 These findings suggest that ASA enhances PDLSC function and may be useful in regener

251 al Tuberculosis Association and in 1939, the ASA became the American Trudeau Society, cosmetic revisi

252 Data derived from the ASA Closed Claims Project suggests that malpractice clai

253 otein misfolding process act as seeds in the ASA for HD.

254 Major ions in the ASA fraction showed elevated accumulation rates of Ca, K

255 The incidence of VTE was 2.27% in the ASA group and 1.20% in the LMWH group.

256 ism was observed in 1.70% of patients in the ASA group and none in the LMWH group.

257 dence interval, -1.69-3.83; P = .452) in the ASA group.

258 analogous physical model, (b) to measure the ASA and VSA throughout the cardiac cycle in healthy volu

259 do so, demonstrating the specificity of the ASA.

260 In the ticagrelor-ASA >300 mg cohort, all-cause and vascular mortality wer

261 Moreover, the ticagrelor-ASA interaction was not significant by any multivariate

262 analysis, patients were grouped according to ASA dose: 81 mg (n = 1285), 325 mg (n = 1004), and none

263 ) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA,

264 fically, 119 subjects had index reactions to ASA doses lower than 300 mg.

265 ons; 86 of the latter had index reactions to ASA doses of 300 mg or less.

266 d histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, shoul

267 s of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable.

268 eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake.

269 ompetitive partial inhibitor with respect to ASA, and binds to all forms of the enzyme with a Ki near

270 At V2, the majority (24; 63.15%) tolerated ASA and other NSAIDs (Group A) while 14 (36.84%) still r

271 was significantly lower in patients who took ASA 24 hours or less preoperatively (1.5%) than in those

272 ApoE-II was also superior to wild-type ASA in reducing lysosomal storage in the CNS of ASA-knoc

273 In contrast to wild-type ASA, which is taken up by mannose-6-phosphate receptors,

274 .8%) underwent SM and 4862 (43.2%) underwent ASA.

275 OMR for each site of age, admission urgency, ASA score, and procedure type.

276 ve body mass index (BMI), heavy alcohol use, ASA (American Society of Anesthesiologists) score greate

277 is large series, increased BMI, alcohol use, ASA class greater than 2, flap failure, and prolonged op

278 A simple integer-based score using ASA class and the LOS predicted risk of readmission (are

279 2.9 (95% confidence interval, 1.2-7.0 versus ASA 81 mg+dipyridamole; P = 0.02) and 3.4 (95% confidenc

280 3.4 (95% confidence interval, 1.2-9.5 versus ASA 81 mg; P = 0.02) for hemorrhagic events.

281 apy and 8,962 (13%) with dual-therapy (VKA + ASA).

282 .03-3.41) were significantly associated with ASA prescription.

283 of CVD and identify factors associated with ASA prescription.

284 he primary end point was ulcer bleeding with ASA use in 5048 patient-years of follow-up evaluation.

285 m incidence of recurrent ulcer bleeding with ASA use is low after H pylori infection is eradicated.

286 were prospectively re-evaluated by DPT with ASA/other NSAIDs at two time points between 2013 and 201

287 Rescue experiments with ASA showed a normalization of the ratio of long versus s

288 antiplatelet, and transfusion increased with ASA-anticoagulant (hazard ratio, 6.1; 95% confidence int

289 with aspirin-tolerant asthma, patients with ASA had increased bronchial mucosal neutrophil and eosin

290 Patients with ASA physical status I, II, III, IV or V were assigned ei

291 id desensitization protocol in patients with ASA sensitivity undergoing coronary angiography.

292 ronchial biopsy specimens from patients with ASA, patients with aspirin-tolerant asthma, and control

293 tis to the bronchial mucosa in patients with ASA.

294 Subjects with ASA have been reported to develop long-term complication

295 y (age: 56+/-14 years, men 55%) treated with ASA.

296 ost reduction in patients over 75 years with ASA I-II undergoing colonic resection, and the largest c

297 cost increase in patients over 75 years with ASA III-IV undergoing rectal resection as compared with

298 paroscopy ranged from &OV0556;409 (<75 years ASA I-II) to &OV0556;1932 (>/=75 years ASA I-II).

299 l costs, ranging from &OV0556;501 (<75 years ASA I-II) to &OV0556;2515 (>/=75 years ASA III-IV).

300 years ASA I-II) to &OV0556;1932 (>/=75 years ASA I-II).

301 years ASA I-II) to &OV0556;2515 (>/=75 years ASA III-IV).